<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38617937</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>Lower prevalence of post-Covid-19 Condition following Omicron SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>e28941</StartPage><MedlinePgn>e28941</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e28941</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2024.e28941</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">Different SARS-CoV-2 variants can differentially affect the prevalence of Post Covid-19 Condition (PCC). This prospective study assesses prevalence and severity of symptoms three months after an Omicron infection, compared to Delta, test-negative and population controls. This study also assesses symptomology after reinfection and breakthrough infections.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">After a positive SARS-CoV-2 test, cases were classified as Omicron or Delta based on &#x2265; 85% surveillance prevalence. Three months after enrolment, participants indicated point prevalence for 41 symptoms and severity, using validated questionnaires for four symptoms. PCC prevalence was estimated as the difference in prevalence of at least one significantly elevated symptom, identified by permutation test, in cases compared to population controls.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">At three months follow-up, five symptoms and severe dyspnea were significantly elevated in Omicron cases (n&#xa0;=&#xa0;4138) compared to test-negative (n&#xa0;=&#xa0;1672) and population controls (n&#xa0;=&#xa0;2762). PCC prevalence was 10&#xb7;4% for Omicron cases and 17&#xb7;7% for Delta cases (n&#xa0;=&#xa0;6855). In Omicron cases, severe fatigue and dyspnea were more prevalent in reinfected than primary infected, while severity of symptoms did not significantly differ between cases with a booster or primary vaccination course.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Prevalence of PCC is 41% lower after Omicron than Delta at three months. Reinfection seems associated with more severe long-term symptoms compared to first infection.</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Bruijn</LastName><ForeName>Sim&#xe9;on</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Hoek</LastName><ForeName>Albert Jan</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mutubuki</LastName><ForeName>Elizabeth N</ForeName><Initials>EN</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knoop</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medical Psychology and Amsterdam Public Health from the Amsterdam UMC, Location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slootweg</LastName><ForeName>Jaap</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Sustainability, Environment and Health, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tulen</LastName><ForeName>Anna D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franz</LastName><ForeName>Eelco</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Wijngaard</LastName><ForeName>Cees C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Maaden</LastName><ForeName>Tessa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Delta</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Long-term symptoms</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">Post Covid-19 condition</Keyword><Keyword MajorTopicYN="N">Prevalence</Keyword><Keyword MajorTopicYN="N">Reinfection</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Symptoms</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>15</Day><Hour>4</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38617937</ArticleId><ArticleId IdType="pmc">PMC11015416</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2024.e28941</ArticleId><ArticleId IdType="pii">S2405-8440(24)04972-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  WHO coronavirus (COVID-19) dashboard. 2021. https://covid19.who.int/ Access date 4 May 2022. 4 May 2022]; Available from:</Citation></Reference><Reference><Citation>Groff D., et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw. Open. 2021;4(10) doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums D.V. Editorial: long COVID, or post-COVID syndrome, and the global impact on health care. Med. Sci. Mon. Int. Med. J. Exp. Clin. Res. 2021:27. doi: 10.12659/MSM.933446.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.933446</ArticleId><ArticleId IdType="pmc">PMC8194290</ArticleId><ArticleId IdType="pubmed">34092779</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2021 doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C., et al. Long-COVID symptoms in individuals infected with different SARS-CoV-2 variants of concern: a systematic review of the literature. Viruses. 2022;14(12) doi: 10.3390/v14122629.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14122629</ArticleId><ArticleId IdType="pmc">PMC9785120</ArticleId><ArticleId IdType="pubmed">36560633</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C., et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022;399(10335):1618&#x2013;1624. doi: 10.1016/S0140-6736(22)00327-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00327-0</ArticleId><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B., Xie Y., Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat. Med. 2022;28(11):2398&#x2013;2405. doi: 10.1038/s41591-022-02051-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02051-3</ArticleId><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Maaden T., et al. Prevalence and severity of symptoms 3 Months after infection with SARS-CoV-2 compared to test-negative and population controls in The Netherlands. J. Infect. Dis. 2022:1537&#x2013;6613. doi: 10.1093/infdis/jiac474. (Electronic)</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac474</ArticleId><ArticleId IdType="pubmed">36477364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering, A.V., S.K.R. van Zon, T.C. Olde Hartman, and J.G.M. Rosmalen, Persistence of Somatic Symptoms after COVID-19 in the Netherlands: an Observational Cohort Study. (1474-547X (Electronic)) doi.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., et al. Global prevalence of post COVID-19 condition or long covid: a meta-analysis and systematic review. J. Infect. Dis. 2022;226(9):1593&#x2013;1607. doi: 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijksinstituut voor Volksgezondheid en Milieu (RIVM) Covid-19 aantallen per gemeente per publicatiedatum. 2022 https://data.rivm.nl/covid-19/ 31-10-2022]; Available from:</Citation></Reference><Reference><Citation>Mutubuki E.N., et al. Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study) BMJ Open. 2022;12(7) doi: 10.1136/bmjopen-2022-062439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-062439</ArticleId><ArticleId IdType="pmc">PMC9251892</ArticleId><ArticleId IdType="pubmed">35777877</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijksinstituut voor Volksgezondheid en Milieu (RIVM)  Covid-19 rapportage van SARS-CoV-2 varianten in Nederland via de aselecte steekproef van RT-PCR positieve monsters in de nationale kiemsurveillance. 2022. https://data.rivm.nl/covid-19/ [cited 2022 11-02-2022]; Available from:</Citation></Reference><Reference><Citation>Worm-Smeitink M., et al. The assessment of fatigue: psychometric qualities and norms for the Checklist individual strength. J. Psychosom. Res. 2017;98:40&#x2013;46. doi: 10.1016/j.jpsychores.2017.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2017.05.007</ArticleId><ArticleId IdType="pubmed">28554371</ArticleId></ArticleIdList></Reference><Reference><Citation>Vercoulen J.H., et al. Dimensional assessment of chronic fatigue syndrome. J. Psychosom. Res. 1994;38(5):383&#x2013;392. doi: 10.1016/0022-3999(94)90099-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3999(94)90099-x</ArticleId><ArticleId IdType="pubmed">7965927</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponds R., Van Boxtel M., Jolles J. De cognitive failure questionnaire als maat voor subjectief cognitief functioneren. Tijdschr. Neuropsychol. 2006;(2):37&#x2013;45.</Citation></Reference><Reference><Citation>Broadbent D.E., Cooper P.F., FitzGerald P., Parkes K.R. The cognitive failures questionnaire (CFQ) and its correlates. Br. J. Clin. Psychol. 1982;21(1):1&#x2013;16. doi: 10.1111/j.2044-8260.1982.tb01421.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2044-8260.1982.tb01421.x</ArticleId><ArticleId IdType="pubmed">7126941</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee K.I., Sanderman R. Research Institute SHARE; 2012. Het meten van de algemene gezondheidstoestand met de RAND-36, een handleiding: umcg/Rijksuniversiteit groningen.</Citation></Reference><Reference><Citation>Mahler D.A., Wells C.K. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580&#x2013;586. doi: 10.1378/chest.93.3.580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.93.3.580</ArticleId><ArticleId IdType="pubmed">3342669</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouwmans C., et al. Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P) BMC Health Serv. Res. 2013;13:217. doi: 10.1186/1472-6963-13-217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6963-13-217</ArticleId><ArticleId IdType="pmc">PMC3694473</ArticleId><ArticleId IdType="pubmed">23768141</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg Y., Benjamini Y. More powerful procedures for multiple significance testing. Stat. Med. 1990;9(7):811&#x2013;818. doi: 10.1002/sim.4780090710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.4780090710</ArticleId><ArticleId IdType="pubmed">2218183</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M., et al. Prevalence of post-coronavirus disease condition 12 Weeks after omicron infection compared with negative controls and association with vaccination status. Clin. Infect. Dis. 2022;76(9):1567&#x2013;1575. doi: 10.1093/cid/ciac947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac947</ArticleId><ArticleId IdType="pubmed">36519381</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., et al. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399(10343):2263&#x2013;2264. doi: 10.1016/S0140-6736(22)00941-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiliopoulos L., et al. Post-acute symptoms four months after SARS-CoV-2 infection during the Omicron period: a nationwide Danish questionnaire study. medRxiv. 2022;(22280990):2022.10.12. doi: 10.1101/2022.10.12.22280990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.10.12.22280990</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson, K., et al., Post-covid medical complaints after SARS-CoV-2 Omicron vs Delta variants - a prospective cohort study. medRxiv, 2022: p. 2022.05.23.22275445 doi: 10.1101/2022.05.23.22275445.</Citation></Reference><Reference><Citation>Buonsenso D., et al. Risk of long Covid in children infected with Omicron or pre-Omicron SARS-CoV-2 variants. Acta Paediatr. 2023;112(6):1284&#x2013;1286. doi: 10.1111/apa.16764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.16764</ArticleId><ArticleId IdType="pubmed">36938946</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg, Y., et al., Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. (1533-4406 (Electronic)) doi.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9165562</ArticleId><ArticleId IdType="pubmed">35613036</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B., Xie Y. 2022. Outcomes of SARS-CoV-2 Reinfection.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1749502/v1</ArticleId><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, P., J.A.-O. Liu, and M.A.-O. Liu, Effect of COVID-19 Vaccines on Reducing the Risk of Long COVID in the Real World: A Systematic Review and Meta-Analysis. LID - 10.3390/ijerph191912422 [doi] LID - 12422. (1660-4601 (Electronic)) doi.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9566528</ArticleId><ArticleId IdType="pubmed">36231717</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B., Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med. 2022 doi: 10.1038/s41591-022-01840-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballouz T., et al. Post COVID-19 condition after Wildtype, Delta, and Omicron variant SARS-CoV-2 infection and vaccination: pooled analysis of two population-based cohorts. medRxiv. 2022:2022.09. doi: 10.1101/2022.09.25.22280333. 25.22280333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.09.25.22280333</ArticleId><ArticleId IdType="pmc">PMC9946205</ArticleId><ArticleId IdType="pubmed">36812215</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou G.N., et al. Effectiveness of mRNA COVID-19 vaccine boosters against infection, hospitalization, and death: a target trial emulation in the omicron (B.1.1.529) variant era. Ann. Intern. Med. 2022 doi: 10.7326/m22-1856.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/m22-1856</ArticleId><ArticleId IdType="pmc">PMC9575390</ArticleId><ArticleId IdType="pubmed">36215715</ArticleId></ArticleIdList></Reference><Reference><Citation>Go&#xeb;rtz Y.M.J., et al. Fatigue in patients with chronic disease: results from the population-based Lifelines Cohort Study. Sci. Rep. 2021;11(1) doi: 10.1038/s41598-021-00337-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-00337-z</ArticleId><ArticleId IdType="pmc">PMC8546086</ArticleId><ArticleId IdType="pubmed">34697347</ArticleId></ArticleIdList></Reference><Reference><Citation>Ursinus J., et al. Prevalence of persistent symptoms after treatment for lyme borreliosis: a prospective observational cohort study. The Lancet Regional Health &#x2013; Europe. 2021:6. doi: 10.1016/j.lanepe.2021.100142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100142</ArticleId><ArticleId IdType="pmc">PMC8454881</ArticleId><ArticleId IdType="pubmed">34557833</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>